Aquavit has submitted an investigational new drug (IND) application to the Food and Drug Administration (FDA) for the initiation of its Phase II/III study of Dermatox (aqubotulinumtoxinA), an intradermal injection of botulinum toxin.

It is intended for the temporary improvement of mild to moderate face and neck lines and skin quality.

Titled ‘Safety and Efficacy of AqubotulinumtoxinA for Enhanced Skin Quality Index (SAFESQIN)’, the study will enrol adults younger than 65 years of age.

Aquavit CEO Sobin Chang said: “We are excited about the clinical trials of Dermatox and strongly believe in its ability to thrive in the ultra-competitive dermatology space.”

Physicians will be able to safely address the skin’s thinner layers to improve quality and reduce fine lines on a broad surface, including the complete area of the face and neck.

Aquavit CMO Churlsu Kwon said: “While existing botulinum toxins focus only on intramuscular injections of moderate to severe lines on a very specific area, Dermatox would be the first approved for the improvement of overall skin quality, cementing Dermatox as a groundbreaking treatment option.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

AqubotulinumtoxinA has also been approved for use in Asia, South America and the Middle East.

It is also currently in phase III clinical trials in many other territories.